| scholarly article | Q13442814 |
| P2093 | author name string | E A Eisenhauer | |
| J J Biagi | |||
| S L Ellard | |||
| U Lee | |||
| R Grimshaw | |||
| H Hirte | |||
| A M Oza | |||
| H I Chalchal | |||
| J Sederias | |||
| S P Ivy | |||
| P2860 | cites work | Cancer statistics, 2008 | Q27860585 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study | Q28258045 | ||
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial | Q28268831 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer | Q30422736 | ||
| Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer | Q33369361 | ||
| Angiogenesis in epithelian ovarian cancer | Q33919078 | ||
| Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer | Q34582674 | ||
| Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens | Q36292546 | ||
| Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels | Q36431375 | ||
| Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. | Q40343201 | ||
| Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia | Q46114146 | ||
| Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane | Q46696565 | ||
| Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions | Q46730085 | ||
| Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma | Q46837791 | ||
| Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer | Q46892024 | ||
| Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). | Q47936662 | ||
| Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. | Q53300225 | ||
| P433 | issue | 2 | |
| P921 | main subject | peritoneal carcinoma | Q1816041 |
| patient | Q181600 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 335-340 | |
| P577 | publication date | 2010-08-12 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. | |
| P478 | volume | 22 |
| Q43902249 | A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia |
| Q64124105 | A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254) |
| Q54526385 | A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor mo |
| Q52628568 | A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. |
| Q38553247 | An overview of early investigational therapies for chemoresistant ovarian cancer. |
| Q38631373 | An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. |
| Q38071555 | Angiogenesis inhibitors in the treatment of epithelial ovarian cancer |
| Q37945089 | Anti-angiogenic agents in ovarian cancer: dawn of a new era? |
| Q38115596 | Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment |
| Q35205410 | Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. |
| Q33572395 | Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based Medicine |
| Q38627885 | Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib |
| Q33662162 | Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review |
| Q26779120 | Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer |
| Q38151193 | Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer |
| Q36122605 | Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis |
| Q38038489 | Clinical trials and future potential of targeted therapy for ovarian cancer |
| Q36171268 | Clinical utility of targeted treatments in the management of epithelial ovarian cancer |
| Q27023510 | Contemporary use of bevacizumab in ovarian cancer |
| Q38751236 | Current and emerging treatment options in the management of advanced ovarian cancer |
| Q26861293 | Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer |
| Q38497958 | Emerging therapies: angiogenesis inhibitors for ovarian cancer |
| Q38123207 | Genetic changes in nonepithelial ovarian cancer |
| Q59430751 | Hypertension in cancer patients treated with anti-angiogenic based regimens |
| Q38370237 | Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers. |
| Q33920800 | Investigational agents in development for the treatment of ovarian cancer |
| Q37888659 | Molecular targeted therapy in ovarian cancer: what is on the horizon? |
| Q38175506 | New biological treatments for gynecological tumors: focus on angiogenesis |
| Q28082524 | New perspectives on targeted therapy in ovarian cancer |
| Q55332470 | Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. |
| Q47424260 | Novel antiangiogenic therapies in ovarian cancer |
| Q37984612 | Novel targets for VEGF-independent anti-angiogenic drugs. |
| Q38040628 | Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents. |
| Q38682200 | Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. |
| Q36648394 | Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options |
| Q43471758 | Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer |
| Q26751280 | Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives |
| Q37951860 | Recurrent ovarian cancer: when and how to treat |
| Q42369233 | Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer |
| Q36308299 | RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer |
| Q38071132 | Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis |
| Q36880907 | Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs |
| Q83840457 | Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer |
| Q26783748 | Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages |
| Q35864802 | Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase |
| Q26750649 | Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments |
| Q26830287 | Targeted anti-vascular therapies for ovarian cancer: current evidence |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q63359576 | Targeted therapy in ovarian cancer |
| Q35088311 | Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies |
| Q26824766 | Targeting angiogenesis in gynecologic cancers |
| Q38118388 | Targeting tyrosine-kinases in ovarian cancer |
| Q30248645 | The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review |
| Q38048887 | The changing landscape of therapeutic strategies for recurrent ovarian cancer |
| Q38144166 | The potential of sunitinib as a therapy in ovarian cancer |
| Q50345037 | The rise of genomic profiling in ovarian cancer |
| Q37937859 | The role of targeted therapy in ovarian cancer |
| Q33770035 | Therapeutic strategies for targeting the ovarian tumor stroma |
| Q98771756 | Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy |
Search more.